Pretreatment patient characteristics
| . | Cohorts 1 and 2 . | Cohort 3 . |
|---|---|---|
| No. patients | 23 | 19 |
| Median age, y (range) | 61 (44-84) | 55 (39-69) |
| Stage, % | ||
| Rai intermediate risk | 39 | 11 |
| Rai high risk | 61 | 89 |
| Female, % | 35 | 16 |
| Median no. therapies (range) | 4 (2-13) | 4 (1-9) |
| Prior fludarabine treatment, no. (%) | 22 (96) | 19 (100) |
| Fludarabine refractory, no. (%) | 17 (74) | 18 (95) |
| Del(11q22.3), % | 39 | 47 |
| Del(17p13.1), % | 35 | 21 |
| Complex karyotype, % | 35 | 53 |
| Complex, del(11q22.3), or del(17p13.1), % | 70 | 79 |
| Median leukocyte count, ×109/L (range) | 8.3 (3.1-200) | 44.5 (1.9-253) |
| Median hemoglobin, mM (range) | 10.1 (6.5-15.4) | 9.5 (5.8-13.7) |
| Median platelets, ×109/L (range) | 117 (53-254) | 64 (16-213) |
| Patients with splenomegaly, % | 39 | 74 |
| Patients with adenopathy, % | 100 | 100 |
| Patients with bulky adenopathy above 5 cm, % | 87 | 63 |
| Patients with bulky adenopathy above 10 cm, % | 26 | 37 |
| . | Cohorts 1 and 2 . | Cohort 3 . |
|---|---|---|
| No. patients | 23 | 19 |
| Median age, y (range) | 61 (44-84) | 55 (39-69) |
| Stage, % | ||
| Rai intermediate risk | 39 | 11 |
| Rai high risk | 61 | 89 |
| Female, % | 35 | 16 |
| Median no. therapies (range) | 4 (2-13) | 4 (1-9) |
| Prior fludarabine treatment, no. (%) | 22 (96) | 19 (100) |
| Fludarabine refractory, no. (%) | 17 (74) | 18 (95) |
| Del(11q22.3), % | 39 | 47 |
| Del(17p13.1), % | 35 | 21 |
| Complex karyotype, % | 35 | 53 |
| Complex, del(11q22.3), or del(17p13.1), % | 70 | 79 |
| Median leukocyte count, ×109/L (range) | 8.3 (3.1-200) | 44.5 (1.9-253) |
| Median hemoglobin, mM (range) | 10.1 (6.5-15.4) | 9.5 (5.8-13.7) |
| Median platelets, ×109/L (range) | 117 (53-254) | 64 (16-213) |
| Patients with splenomegaly, % | 39 | 74 |
| Patients with adenopathy, % | 100 | 100 |
| Patients with bulky adenopathy above 5 cm, % | 87 | 63 |
| Patients with bulky adenopathy above 10 cm, % | 26 | 37 |